These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
641 related articles for article (PubMed ID: 3096633)
1. Progestins and oral contraceptive-induced lipoprotein changes: a prospective study. Lipson A; Stoy DB; LaRosa JC; Muesing RA; Cleary PA; Miller VT; Gilbert PR; Stadel B Contraception; 1986 Aug; 34(2):121-34. PubMed ID: 3096633 [TBL] [Abstract][Full Text] [Related]
2. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids. Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162 [TBL] [Abstract][Full Text] [Related]
3. A prospective controlled study of the effect on blood pressure of contraceptive preparations containing different types and dosages of progestogen. Wilson ES; Cruickshank J; McMaster M; Weir RJ Br J Obstet Gynaecol; 1984 Dec; 91(12):1254-60. PubMed ID: 6440589 [TBL] [Abstract][Full Text] [Related]
4. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785 [TBL] [Abstract][Full Text] [Related]
5. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters. Wiegratz I; Jung-Hoffmann C; Gross W; Kuhl H Contraception; 1998 Aug; 58(2):83-91. PubMed ID: 9773262 [TBL] [Abstract][Full Text] [Related]
6. Comparative studies of the ethynyl estrogens used in oral contraceptives. VII. Effects with and without progestational agents on ultracentrifugally fractionated plasma lipoproteins in humans, baboons, and beagles. Goldzieher JW; Chenault CB; de la Peña A; Dozier TS; Kraemer DC Fertil Steril; 1978 Nov; 30(5):522-33. PubMed ID: 214353 [TBL] [Abstract][Full Text] [Related]
7. The varying effects of progestins on lipid levels and cardiovascular disease. La Rosa JC Am J Obstet Gynecol; 1988 Jun; 158(6 Pt 2):1621-9. PubMed ID: 3132043 [TBL] [Abstract][Full Text] [Related]
8. [Influence of progestins on adverse effects of oral contraceptives]. Wynn V Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210 [TBL] [Abstract][Full Text] [Related]
9. Fasting plasma lipids, lipoproteins and apolipoproteins in Nigerian women using combined oral and progestin-only injectable contraceptives. Oyelola OO Contraception; 1993 May; 47(5):445-54. PubMed ID: 8513671 [TBL] [Abstract][Full Text] [Related]
10. Comparative metabolic effects of three types of combined oral contraceptive pills in Chinese women. Prasad RN; Liew D; Ratnam SS Contraception; 1989 Jan; 39(1):21-35. PubMed ID: 2521321 [TBL] [Abstract][Full Text] [Related]
11. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring. Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404 [TBL] [Abstract][Full Text] [Related]
12. A norgestimate-containing oral contraceptive: review of clinical studies. Kafrissen ME Am J Obstet Gynecol; 1992 Oct; 167(4 Pt 2):1196-202. PubMed ID: 1415446 [TBL] [Abstract][Full Text] [Related]
13. Oral contraceptive tablets containing 20 and 30 micrograms of ethinyl estradiol with 150 micrograms desogestrel. Their influence on lipids, lipoproteins, sex hormone binding globulin and testosterone. Akerlund M; Almström E; Högstedt S; Nabrink M Acta Obstet Gynecol Scand; 1994 Feb; 73(2):136-43. PubMed ID: 8116352 [TBL] [Abstract][Full Text] [Related]
14. Oral contraceptives and cardiovascular risk. Taking a safe course of action. Derman RJ Postgrad Med; 1990 Sep; 88(4):119-22. PubMed ID: 2204902 [TBL] [Abstract][Full Text] [Related]
15. A randomized comparative open study of the effects of two oral contraceptives, Triphasil and Ortho 7/7/7, on lipid metabolism. Kakis G; Powell M; Marshall A; Steiner G Contraception; 1993 Feb; 47(2):131-48. PubMed ID: 8449014 [TBL] [Abstract][Full Text] [Related]
16. Plasma lipoproteins and fatty acid composition after "minipill". Sassolas A; Lagarde M; Guichardant M; Quincy C; Dechavanne M Contraception; 1983 Oct; 28(4):357-68. PubMed ID: 6421540 [TBL] [Abstract][Full Text] [Related]
17. Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: relationships to estrogen and progestin potency. Knopp RH; Walden CE; Wahl PW; Hoover JJ; Warnick GR; Albers JJ; Ogilvie JT; Hazzard WR J Clin Endocrinol Metab; 1981 Dec; 53(6):1123-32. PubMed ID: 7298796 [TBL] [Abstract][Full Text] [Related]
18. Effects of three low-dose oral contraceptive formulations on lipid metabolism. Bertolini S; Elicio N; Cordera R; Gapitanio GL; Montagna G; Croce S; Saturnino M; Balestreri R; De Cecco L Acta Obstet Gynecol Scand; 1987; 66(4):327-32. PubMed ID: 2962417 [TBL] [Abstract][Full Text] [Related]
19. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499 [TBL] [Abstract][Full Text] [Related]
20. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins. Crook D; Godsland IF; Worthington M; Felton CV; Proudler AJ; Stevenson JC Am J Obstet Gynecol; 1993 Nov; 169(5):1183-9. PubMed ID: 8238183 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]